Table 4 Clinical chemistry in the PLF at week 13 of the experimental period
Test article | Total dose (mg/kg) | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|
LDH | μ-TP | μ-ALB | LDH | μ-TP | μ-ALB | ||||
(U/L) | (mg/dL) | (µg/mL) | (U/L) | (mg/dL) | (µg/mL) | ||||
Nontreatment | - | (5) | 25 ± 39 | 29.8 ± 6.0 | 68.2 ± 9.9 | (5) | 2 ± 1 | 19.2 ± 5.5 | 50.2 ± 7.8 |
Control | 0 | (5) | 7 ± 2 | 26.8 ± 2.5 | 63.7 ± 4.4 | (5) | 3 ± 3 | 17.1 ± 3.1 | 45.0 ± 5.0 |
MWNT-7 | 0.128 | (5) | 11 ± 7 | 31.4 ± 3.7 | 72.5 ± 6.5 | (5) | 4 ± 2 | 22.7 ± 1.3# | 59.4 ± 2.3# |
MWNT-7 | 0.64 | (5) | 11 ± 5 | 35.3 ± 8.0 | 76.3 ± 9.4 | (5) | 4 ± 1 | 23.7 ± 1.5# | 57.5 ± 4.3# |
MWNT-7 | 3.2 | (1) | 15 ± 6 | 39.6 ± 5.1## | 83.9 ± 10.5## | (5) | 8 ± 11 | 37.3 ± 23.8# | 79.8 ± 38.7# |
VGCF™-H | 0.128 | (5) | 9 ± 3 | 30.5 ± 1.9 | 72.0 ± 5.0 | (5) | 4 ± 2 | 20.0 ± 3.4 | 53.1 ± 7.3 |
VGCF™-H | 0.64 | (5) | 14 ± 12 | 31.5 ± 4.8 | 74.3 ± 9.5# | (5) | 4 ± 2 | 19.3 ± 2.3 | 50.9 ± 7.5 |
VGCF™-H | 3.2 | (5) | 7 ± 4 | 29.9 ± 2.9 | 69.2 ± 3.9 | (5) | 3 ± 1 | 19.6 ± 4.6 | 49.7 ± 8.7 |